Can Ampligen’s Phase 3 push reshape pancreatic cancer treatment? Read how AIM ImmunoTech’s latest clinical progress could change the oncology outlook.
Avacta opens Phase 1 trial of FAP-Exd (AVA6103) in four advanced solid tumors. Analysis of what the sustained-release exatecan conjugate must prove in 2026.
ARPA-H backs Seaport Therapeutics’ GlyphCele program targeting gut lymphatics in metabolic disease and pancreatic cancer. Read the analysis.
Can Propanc Biopharma’s PRP therapy disrupt pancreatic cancer treatment? Explore the science, risks, and market implications of this emerging oncology approach.
ClearNote Health’s updated Avantect test improves pancreatic cancer detection in high-risk patients. Find out what this changes for early screening strategies.
Explore what AIM ImmunoTech’s Ampligen Phase 2 data could change for pancreatic cancer immunotherapy and what risks still remain.
Can PRP’s proenzyme approach change pancreatic cancer treatment strategy? Explore what Propanc Biopharma’s data means for oncology innovation.
GT Biopharma’s GTB-5550 gets FDA clearance for a Phase 1 solid tumor trial. Find out how this NK cell engager could reshape B7-H3 cancer immunotherapy.
Find out how zenocutuzumab could change treatment strategies in NRG1+ pancreatic cancer after progression. Explore new ASCO GI 2026 data today.
Indivumed GmbH and the Wilmot Cancer Institute at the University of Rochester Medical Center have expanded their collaboration to accelerate the development of patient-derived tumor models and AI-informed therapeutic discovery for solid tumors with high unmet clinical need. What this collaboration changes for the cancer model ecosystem The expansion of the Indivumed and University of […]